Prophylactic treatment in hemophilic patients with inhibitors

被引：1
作者：
Haya, Saturnino [1 ]
机构：
[1] La Fe Univ & Polytech Hosp, Dept Hematol, Haemostasis & Thrombosis Unit, Valencia, Spain
来源：
BLOOD COAGULATION & FIBRINOLYSIS | 2019年 / 30卷
关键词：
haemophilia; inhibitors; prophylactic treatment;
D O I：
10.1097/MBC.0000000000000823
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The development of inhibitors continues to be the most important complication in severe hemophilia A. The management of inhibitor patients revolves around two basic principles: eradication of the inhibitor and management and prevention of bleeding. In this paper, we review the prophylactic treatments carried out in the last two decades with the two available bypassing agents and the results of the clinical trials carried out with the new molecules under investigation or already licensed for the prevention of hemorrhagic episodes in hemophilia, like emicizumab. Copyright (C) 2019 Wolters Kluwer Health, Inc. All rights reserved.
引用
收藏
页码：S14 / S18
页数：5
相关论文
共 42 条
[1]   Randomized comparison of prophylaxis and on-demand regimens with FEIBA NF in the treatment of haemophilia A and B with inhibitors [J].
Antunes, S. V. ;
Tangada, S. ;
Stasyshyn, O. ;
Mamonov, V. ;
Phillips, J. ;
Guzman-Becerra, N. ;
Grigorian, A. ;
Ewenstein, B. ;
Wong, W. -Y. .
HAEMOPHILIA, 2014, 20 (01) :65-72
[2]   Novel approaches to hemophilia therapy: successes and challenges [J].
Arruda, Valder R. ;
Doshi, Bhavya S. ;
Samelson-Jones, Benjamin J. .
BLOOD, 2017, 130 (21) :2251-2256
[3]   A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers [J].
Cardinal, M. ;
Kantaridis, C. ;
Zhu, T. ;
Sun, P. ;
Pittman, D. D. ;
Murphy, J. E. ;
Arkin, S. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (09) :1722-1731
[4]   Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial [J].
Chowdary, P. ;
Lethagen, S. ;
Friedrich, U. ;
Brand, B. ;
Hay, C. ;
Karim, F. Abdul ;
Klamroth, R. ;
Knoebl, P. ;
Laffan, M. ;
Mahlangu, J. ;
Miesbach, W. ;
Nielsen, J. Dalsgaard ;
Martin-Salces, M. ;
Angchaisuksiri, P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 (05) :743-754
[5]   A retrospective postlicensure survey of FEIBA efficacy and safety [J].
DiMichele, D. ;
Negrier, C. .
HAEMOPHILIA, 2006, 12 (04) :352-362
[6]   Small Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI) [J].
Dockal, Michael ;
Hartmann, Rudolf ;
Fries, Markus ;
Thomassen, M. Christella L. G. D. ;
Heinzmann, Alexandra ;
Ehrlich, Hartmut ;
Rosing, Jan ;
Osterkamp, Frank ;
Polakowski, Thomas ;
Reineke, Ulrich ;
Griessner, Andreas ;
Brandstetter, Hans ;
Scheiflinger, Friedrich .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2014, 289 (03) :1732-1741
[7]   A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A [J].
Eichler, H. ;
Angchaisuksiri, P. ;
Kavakli, K. ;
Knoebl, P. ;
Windyga, J. ;
Jimenez-Yuste, V. ;
Hyseni, A. ;
Friedrich, U. ;
Chowdary, P. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2018, 16 (11) :2184-2195
[8]   Concizumab restores thrombin generation potential in patients with haemophilia: Pharmacokinetic/pharmacodynamic modelling results of concizumab phase 1/1b data [J].
Eichler, Hermann ;
Angchaisuksiri, Pantep ;
Kavakli, Kaan ;
Knoebl, Paul ;
Windyga, Jerzy ;
Jimenez-Yuste, Victor ;
Delff, Philip Harder ;
Chowdary, Pratima .
HAEMOPHILIA, 2019, 25 (01) :60-66
[9]   Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: A prospective clinical case series [J].
Ettingshausen, C. Escuriola ;
Kreuz, W. .
HAEMOPHILIA, 2010, 16 (01) :90-100
[10]   Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors [J].
Ewing, N. ;
Escuriola-Ettingshausen, C. ;
Kreuz, W. .
HAEMOPHILIA, 2015, 21 (03) :358-364
12345